Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne.

摘要: Objective To determine if treatment with subantimicrobial-dose (SD) doxycycline hyclate (20-mg tablets taken twice daily) improved clinical outcome, had any detectable effect on skin flora, led to overgrowth or colonization of by opportunistic pathogens, resulted in an increase antibiotic resistance the surface microflora patients moderate acne compared placebo. Design Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial. Setting Two university-based clinics. Subjects Adults (N = 51) facial acne. Interventions Patients were randomized receive SD (Periostat; CollaGenex Pharmaceuticals Inc, Newtown, Pa) placebo daily for 6 months. Main Efficacy Outcomes Primary: changes from baseline numbers inflammatory, noninflammatory, and total lesions. Secondary: individual counts papules, pustules, nodules global assessments improvement patient physician. Results Forty completed months treatment. At months, group a significantly greater percent reduction number comedones ( P .03). There no significant differences microbial between groups evidence change susceptibility potential pathogens. The was well tolerated. Conclusions Twice-daily reduced inflammatory noninflammatory lesions acne, tolerated, antimicrobial did not result severity resistant organisms.